Cargando…

Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials

BACKGROUND: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is impair...

Descripción completa

Detalles Bibliográficos
Autores principales: Haney, Sarah, Hancox, Robert J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1821019/
https://www.ncbi.nlm.nih.gov/pubmed/17341317
http://dx.doi.org/10.1186/1465-9921-8-19
_version_ 1782132668165521408
author Haney, Sarah
Hancox, Robert J
author_facet Haney, Sarah
Hancox, Robert J
author_sort Haney, Sarah
collection PubMed
description BACKGROUND: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is impaired. We assessed the effect of long-acting beta-agonist treatment on the response to 5 mg nebulised salbutamol and to ipratropium bromide. METHODS: Two double-blind, placebo-controlled, crossover studies of inhaled formoterol 12 μg twice daily in patients with asthma. High-dose salbutamol: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled methacholine to produce a 20% fall in FEV(1). Salbutamol 5 mg was then administered via nebuliser and the FEV(1 )was monitored for 20 minutes. Ipratropium: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled 4.5% saline to produce a 20% fall in FEV(1). Salbutamol 200 μg or ipratropium bromide 40 μg was then inhaled and the FEV(1 )was monitored for 30 minutes. Four study arms compared the response to each bronchodilator after formoterol and placebo. Analyses compared the area under the bronchodilator response curves, adjusting for changes in pre-challenge FEV(1), dose of provocational agent and FEV(1 )fall during the challenge procedure. RESULTS: The response to nebulised salbutamol was 15% lower after formoterol therapy compared to placebo (95% confidence 5 to 25%, p = 0.008). The response to ipratropium was unchanged. CONCLUSION: Long-acting beta-agonist treatment induces tolerance to the bronchodilator effect of beta-agonists, which is not overcome by higher dose nebulised salbutamol. However, the bronchodilator response to ipratropium bromide is unaffected.
format Text
id pubmed-1821019
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18210192007-03-14 Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials Haney, Sarah Hancox, Robert J Respir Res Research BACKGROUND: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is impaired. We assessed the effect of long-acting beta-agonist treatment on the response to 5 mg nebulised salbutamol and to ipratropium bromide. METHODS: Two double-blind, placebo-controlled, crossover studies of inhaled formoterol 12 μg twice daily in patients with asthma. High-dose salbutamol: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled methacholine to produce a 20% fall in FEV(1). Salbutamol 5 mg was then administered via nebuliser and the FEV(1 )was monitored for 20 minutes. Ipratropium: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled 4.5% saline to produce a 20% fall in FEV(1). Salbutamol 200 μg or ipratropium bromide 40 μg was then inhaled and the FEV(1 )was monitored for 30 minutes. Four study arms compared the response to each bronchodilator after formoterol and placebo. Analyses compared the area under the bronchodilator response curves, adjusting for changes in pre-challenge FEV(1), dose of provocational agent and FEV(1 )fall during the challenge procedure. RESULTS: The response to nebulised salbutamol was 15% lower after formoterol therapy compared to placebo (95% confidence 5 to 25%, p = 0.008). The response to ipratropium was unchanged. CONCLUSION: Long-acting beta-agonist treatment induces tolerance to the bronchodilator effect of beta-agonists, which is not overcome by higher dose nebulised salbutamol. However, the bronchodilator response to ipratropium bromide is unaffected. BioMed Central 2007 2007-03-06 /pmc/articles/PMC1821019/ /pubmed/17341317 http://dx.doi.org/10.1186/1465-9921-8-19 Text en Copyright © 2007 Haney and Hancox; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Haney, Sarah
Hancox, Robert J
Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
title Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
title_full Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
title_fullStr Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
title_full_unstemmed Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
title_short Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
title_sort overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. two randomised controlled trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1821019/
https://www.ncbi.nlm.nih.gov/pubmed/17341317
http://dx.doi.org/10.1186/1465-9921-8-19
work_keys_str_mv AT haneysarah overcomingbetaagonisttolerancehighdosesalbutamolandipratropiumbromidetworandomisedcontrolledtrials
AT hancoxrobertj overcomingbetaagonisttolerancehighdosesalbutamolandipratropiumbromidetworandomisedcontrolledtrials